Squarepoint’s PMV Pharmaceuticals PMVP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$34K Buy
27,381
+879
+3% +$1.12K ﹤0.01% 4164
2025
Q4
$33.1K Buy
26,502
+13,367
+102% +$17.9K ﹤0.01% 4150
2025
Q3
$18.4K Sell
13,135
-7,770
-37% -$10.7K ﹤0.01% 4291
2025
Q2
$22.2K Sell
20,905
-991
-5% -$972 ﹤0.01% 4386
2025
Q1
$23.9K Sell
21,896
-51,119
-70% -$69.4K ﹤0.01% 4426
2024
Q4
$110K Buy
73,015
+29,722
+69% +$47.1K ﹤0.01% 4675
2024
Q3
$64.5K Sell
43,293
-7,831
-15% -$12.1K ﹤0.01% 3950
2024
Q2
$82.8K Buy
+51,124
New +$92.2K ﹤0.01% 3832
2023
Q3
Sell
-19,041
Closed -$119K 4130
2023
Q2
$119K Sell
19,041
-237,522
-93% -$1.24M ﹤0.01% 3328
2023
Q1
$1.22M Buy
256,563
+238,395
+1,312% +$1.68M 0.01% 1763
2022
Q4
$158K Sell
18,168
-21,603
-54% -$230K ﹤0.01% 2861
2022
Q3
$473K Buy
39,771
+12,300
+45% +$178K ﹤0.01% 2228
2022
Q2
$391K Sell
27,471
-6,585
-19% -$95.8K ﹤0.01% 2136
2022
Q1
$709K Buy
34,056
+6,601
+24% +$116K ﹤0.01% 1804
2021
Q4
$634K Buy
+27,455
New +$663K ﹤0.01% 1993
2020
Q4
Sell
-22,156
Closed -$787K 3185
2020
Q3
$787K Buy
+22,156
New +$815K 0.01% 1125

Other funds holding PMVP

Squarepoint's PMVP Position: Q1 2026 in Review

Squarepoint increased its PMV Pharmaceuticals (PMVP) stake by 3.3% in Q1 2026, buying an estimated $1.12K and bringing the position to 27,381 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #4164.

Squarepoint first reported a position in PMVP in Q3 2020 and has held it in 16 quarters since. The position peaked at $1.22M in Q1 2023. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

  • Squarepoint held 27,381 shares of PMV Pharmaceuticals worth $34K as of Q1 2026.
  • Squarepoint bought 879 PMV Pharmaceuticals shares in Q1 2026, an estimated $1.12K.
  • PMV Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4164 holding.
  • Squarepoint first reported a position in PMV Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
  • Squarepoint's PMV Pharmaceuticals position peaked at $1.22M in Q1 2023.
  • 69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.